Alivus Life Sciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹682 Cr +16% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
AL

Alivus Life Sciences Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Alivus Life Sciences Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹689Cr
+6% YoY
+2.4% QoQ
Net profit
₹163Cr
+14.8% YoY
+8.7% QoQ
Margin
31%
0 pp YoY
−3 pp QoQ
Price₹1,351
Market cap₹16.3K Cr
P/E26.3

The short version

Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business. The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins.

From Alivus Life Sciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business.
  • Overall sales volume growth across segments is significant and expected to persist.
  • New product launches contribute to growth, though not yet a major revenue driver.
  • Capacity expansions (Solapur greenfield, brownfield expansions at Ankleshwar and Dahej) will enable volume and revenue growth post ramp-up.
  • Solapur Phase 1 expected to start with 40-50% utilization, scaling to 60-70% gradually.
  • New launches and pipeline buildup (especially complex molecules and high-potent APIs) underpin medium- to long-term growth.
  • CDMO business ramping up with new projects commencing, supporting future revenue momentum.

2 more points from Alivus Life Sciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments.
  • Entire capex funded through internal accruals.
  • Investments focus on building new capabilities at Solapur (greenfield project) and strengthening the R&D platform.
  • Capacity expansion to increase from 1,198 KL in FY24 to a planned 2,690 KL by FY28.
  • Solapur facility: Phase 1 includes 370 KL for BI block and 120 KL for API block, with 40-50% initial utilization.
  • Brownfield expansions at Ankleshwar and Dahej, with rapid ramp-up expected within 2-3 quarters.
  • Solapur has land bank for additional 700-800 KL capacity, offering runway for 3-4 years.

2 more points from Alivus Life Sciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Alivus Life Sciences operates primarily on long-term contracts in its CDMO business.
  • In the generic API segment, contracts are fewer and typically short-term, lasting about 1-2 years.
  • The company prefers short to medium-term contracts to maintain flexibility due to a dynamic environment.

2 more points from Alivus Life Sciences Ltd's call on order book

Create a free account to keep reading this call

Alivus Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Alivus Life Sciences Ltd Q4 FY26 results — key figures

Alivus Life Sciences Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue689650+6%673+2.4%
Operating profit (EBITDA)215198+8.6%231-6.9%
Operating margin31%31%0 pp34%-3 pp
Profit before tax216191+13.1%198+9.1%
Net profit (PAT)163142+14.8%150+8.7%
EPS (₹)13.2511.58+14.4%12.25+8.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹682 Cr, net profit ₹197 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alivus Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alivus Life Sciences Ltd Q4 FY26 results?

Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business. The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins.

What is Alivus Life Sciences Ltd share price analysis?

Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alivus Life Sciences Ltd planning capital expenditure?

FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments.

Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.